UPDATE: Jefferies Starts Sutro Biopharma (STRO) at Buy

September 2, 2020 4:15 AM EDT
Get Alerts STRO Hot Sheet
Price: $19.76 +1.65%

Rating Summary:
    11 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 22
Trade Now! 
Join SI Premium – FREE
(Updated - September 2, 2020 4:43 AM EDT)

(updating comment)

Jefferies analyst Roger Song initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Buy rating and a price target of $21.00.

The analyst comments "Co has built an advantageous/scalable cell-free protein synthesis platform, XpressCF, and experienced mgmt team has 'cracked the nut' for ADC manufacturing, yielding strong lead assets and LT platform value. '002 could become key Tx in ovarian cancer w/ +ve data in coming months (NT catalyst, ~20-30% upside), and similarly for '001 in liquid tumors. We see sig upside on fundamentals, and under-valued vs. close comps. Thus, we initiate at BUY w/ YE21 PT of $21."

For an analyst ratings summary and ratings history on Sutro Biopharma click here. For more ratings news on Sutro Biopharma click here.

Shares of Sutro Biopharma closed at $10.10 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co